Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1190835 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Tyrosine kinase-activating mutations in Met have been observed in hereditary papillary renal carcinomas as well as in other cancers. These mutations have been examined in several in vitro systems, where they cause constitutive Met activation, focus formation, and cell motility, and are tumorigenic in xenografts. To determine the influence of these mutations on tumorigenesis in vivo, we generated mice with targeted mutations in the murine met locus. Five mouse lines with mutant Met were created: wt, D1226N, Y1228C, M1248T, and M1248T/L1193V. These mouse lines develop a wide range of sarcomas, lymphomas, and carcinomas. To determine if mutationally activated forms of Met have altered signaling specificity we utilized gene expression analysis. Mouse embryonic fibroblasts (MEFs) were isolated from the mutant Met lines and here we present data for wild type and M1248T (M833). Our results indicate that Met activating mutations have unique gene expression signatures. Keywords: mutant analysis Color swapped replicates with common reference
2011-11-20 | E-GEOD-11319 | biostudies-arrayexpress
Project description:Tyrosine kinase-activating mutations in Met have been observed in hereditary papillary renal carcinomas as well as in other cancers. These mutations have been examined in several in vitro systems, where they cause constitutive Met activation, focus formation, and cell motility, and are tumorigenic in xenografts. To determine the influence of these mutations on tumorigenesis in vivo, we generated mice with targeted mutations in the murine met locus. Five mouse lines with mutant Met were created: wt, D1226N, Y1228C, M1248T, and M1248T/L1193V. These mouse lines develop a wide range of sarcomas, lymphomas, and carcinomas. To determine if mutationally activated forms of Met have altered signaling specificity we utilized gene expression analysis. Mouse embryonic fibroblasts (MEFs) were isolated from the mutant Met lines and here we present data for wild type and M1248T (M833). Our results indicate that Met activating mutations have unique gene expression signatures. Keywords: mutant analysis
2011-11-20 | GSE11319 | GEO
Project description:This research will evaluate the role of tissue proteome profile in regional metastatic disease. Considering that one of the main factors of survival in patients with papillary thyroid carcinoma is the presence of regional or distant metastatic disease, this research will focus on the difference in the proteome profiles between papillary thyroid carcinomas which had regional metastatic disease present at the time of surgery, and ones that did not have regional metastatic disease in neck lymph nodes at the time of surgery. In this study, 10 samples of papillary thyroid carcinomas without regional metastatic disease and 10 samples of well-differentiated papillary thyroid carcinomas with regional metastatic disease will be analyzed. The goal of this research is to try to identifiy certain differences in tissue proteomic profiles of papillary thyroid carcinoma depending on the presence of regional metastatic disease in neck lymph nodes.
2025-07-21 | PXD042415 | Pride
Project description:Expression profiling of papillary carcinoma of the breast and grade- and ER-matched cases of invasive ductal breast cancer To identify differential expression between papillary carcinomas of the breast and grade- and ER-matched invasive ductal breast cancers, we performed expression profiling of 16 cases of papillary carcinomas of the breast and 16 cases of grade- and ER-matched invasive ducatal carcinoma of no special subtype. We further reviewed the papillary carcinomas of the breast and classified them into 3 subtypes, namely, invasive papillary carcinoma, encapsulated papillary carcinoma and solid papillary carcinoma. We also performed a hypothesis-generating comparison of differential expression between the 3 subtypes of papillary carcinoma of the breast.
2014-06-20 | GSE55639 | GEO
Project description:Poorly differentiated thyroid carcinomas (PDTC) represent a heterogeneous, aggressive entity, presenting features that suggest a progression from well-differentiated carcinomas. To elucidate the mechanisms underlying such progression and identify novel therapeutical targets, we assessed the genome-wide expression in normal thyroid tissues, well-differentiated thyroid carcinomas and PDTC. RNA were extracted from 2 normal thyroid tissues taken from the opposite lobe of thyroid tumors, and 24 thyroid carcinomas: 5 PDTC, 7 classic papillary thyroid carcinomas (cPTC), 8 follicular variants of PTC (fvPTC) and 4 follicular thyroid carcinomas (FTC). All samples were obtained at time of surgery and immediately frozen in liquid nitrogen. We also hybridized a commercial pool of human thyroid total RNA (BD Bioscience). PTC were screened for BRAF mutations and rearrangements of RET/PTC and, in addition, follicular variants were also analyzed for RAS mutations and PAX8-PPARG rearrangements. FTC were screened for RAS and PAX8-PPARG rearrangements. PDTC were analyzed for BRAF, RAS and PAX8-PPARG genes.
2013-12-10 | E-GEOD-53157 | biostudies-arrayexpress
Project description:Expression profiling of papillary carcinoma of the breast and grade- and ER-matched cases of invasive ductal breast cancer To identify differential expression between papillary carcinomas of the breast and grade- and ER-matched invasive ductal breast cancers, we performed expression profiling of 16 cases of papillary carcinomas of the breast and 16 cases of grade- and ER-matched invasive ducatal carcinoma of no special subtype. We further reviewed the papillary carcinomas of the breast and classified them into 3 subtypes, namely, invasive papillary carcinoma, encapsulated papillary carcinoma and solid papillary carcinoma. We also performed a hypothesis-generating comparison of differential expression between the 3 subtypes of papillary carcinoma of the breast. Expression profiling of 16 cases of papillary carcinioma of the brest and 16 cases of invasive ducal carcinomas using the Illumina HT-12 v4 arrays
2014-06-20 | E-GEOD-55639 | biostudies-arrayexpress
Project description:transcriptome comparison of radiation-induced papillary thyroid carcinomas with sporadic papillary thyroid carcinomas
2005-10-27 | E-MEXP-485 | biostudies-arrayexpress
Project description:Fumarate hydratase (FH) mutation causes hereditary type 2 papillary renal cell carcinoma (HLRCC, Hereditary Leiomyomatosis and Renal Cell Cancer (MM ID # 605839)). The main effect of FH mutation is fumarate accumulation. The current paradigm posits that the main consequence of fumarate accumulation is HIF-a stabilization. Paradoxically, FH mutation differs from other HIF-a stabilizing mutations, such as VHL and SDH mutations, in its associated tumor types. We identified that fumarate can directly up-regulate antioxidant response element (ARE)-controlled genes. We demonstrated that AKR1B10 is an ARE-controlled gene and is up-regulated upon FH knockdown as well as in FH-null cell lines. AKR1B10 overexpression is also a prominent feature in both hereditary and sporadic PRCC2. This phenotype better explains the similarities between hereditary and sporadic PRCC2. Expression profiling renal normal and tumor tissue
2011-10-17 | E-GEOD-26574 | biostudies-arrayexpress
Project description:Sixty-nine (69) tumor samples were collected from patients who underwent thyroidectomy.<br><br>The tumors included 22 benign follicular adenomas, 18 follicular carcinomas, 12 samples of microfollicular adenomas, 4 anaplastic carcinomas, 2 papillary carcinomas, and 9 nodular goiters. 23 samples were obtained from the expression profile repository, Array Express, these counted 14 papillary carcinomas and 9 normal thyroid.
2010-08-05 | E-MEXP-2442 | biostudies-arrayexpress
Project description:Experiment a) Establishment of expression profiles in conventional papillary thyroid carcinomas (PTCs) with a BRAF mutation vs. PTCs without a BRAF mutation and using normal thyroid (TN) specimens as reference. Experiment b) Establishment of expression profiles in follicular adenomas (FAs) of the thyroid and follicular variant of papillary thyroid carcinomas (FVPTCs).
2015-02-16 | GSE54958 | GEO